ABX Advanced Biochemical Compounds GmbH-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ABX Advanced Biochemical Compounds GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010857
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ABX Advanced Biochemical Compounds GmbH (ABX), a subsidiary of Otsuka Holdings Co Ltd is a biochemical compounds provider that manufactures, develops, and distributes biochemicals for nuclear medicine. The company’s products include PET and SPECT precursors and reference standards, reagents kits and cassettes, PET precursors and FDG reagents kits, custom synthesis, particularly kits, peptides, HCI, and radiotracers. It provides pharmaceutical kits and cassettes, APIs, ammpse triflate, precursors, glucose triflates, talose triflates, raclopride, tosyl fallypride, desmethoxyfallypride, fluoroethylspiperone, nitromazenil, flumazenil, harmol, harmine, and etomidate. The company also provides synthesis modules such as ORA NEPTIS mosaic-RS, SIEMENS Explora one, and ORA mosaic-LC and SCINTOMICS, among others. ABX is headquartered in Radeberg, Germany.

ABX Advanced Biochemical Compounds GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Endocyte Enters into Licensing Agreement with ABX 10
Equity Offering 11
Endocyte Raises Funds through Private Placement of Shares and Warrants 11
Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants 12
ABX Advanced Biochemical Compounds GmbH – Key Competitors 13
ABX Advanced Biochemical Compounds GmbH – Key Employees 14
ABX Advanced Biochemical Compounds GmbH – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare, Key Facts 2
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ABX Advanced Biochemical Compounds GmbH, Deals By Therapy Area, 2011 to YTD 2017 8
ABX Advanced Biochemical Compounds GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Endocyte Enters into Licensing Agreement with ABX 10
Endocyte Raises Funds through Private Placement of Shares and Warrants 11
Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants 12
ABX Advanced Biochemical Compounds GmbH, Key Competitors 13
ABX Advanced Biochemical Compounds GmbH, Key Employees 14

★海外企業調査レポート[ABX Advanced Biochemical Compounds GmbH-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Korea Petrochemical Ind. Co Ltd (006650):企業の財務・戦略的SWOT分析
    Summary Korea Petrochemical Ind. Co Ltd (KPICL) is a chemical company that manufactures and markets petrochemical products. The company provides products such as olefins, aromatics, polypropylene, EO and EG, PP and HDPE. It provides olefins products such as ethylene, propylene, butene, butane, isobu …
  • Biolife Solutions Inc (BLFS):企業の財務・戦略的SWOT分析
    Summary Biolife Solutions Inc (BioLife Solutions) is a developer, manufacturer and supplier of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media for cells and tissues. The company offers serum-free and protein-free solutions, which are formulated to red …
  • NV Energy Inc-エネルギー分野:企業M&A・提携分析
    Summary NV Energy, Inc. (NVE), an indirect subsidiary of Berkshire Hathaway Energy Company, is an energy company, which provides a wide range of energy services and products through its principal subsidiaries, Nevada Power Company and Sierra Pacific Power Company. It delivers electricity to a large …
  • PPL Corp (PPL):企業の財務・戦略的SWOT分析
    PPL Corp (PPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • McDonald’s Australia Limited:企業の戦略的SWOT分析
    McDonald's Australia Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Schuler AG:企業の戦略・SWOT・財務情報
    Schuler AG - Strategy, SWOT and Corporate Finance Report Summary Schuler AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • DiaCarta Inc:医療機器:M&Aディール及び事業提携情報
    Summary DiaCarta Inc (DiaCarta) is a developer of molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and also provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation detection ki …
  • Solco Biomedical Co Ltd (043100)-医療機器分野:企業M&A・提携分析
    Summary Solco Biomedical Co Ltd (Solco) is a medical device company that manufactures surgical instruments. The company develops and produces implants for orthopedics, neurosurgery, surgical instruments and home functional health products. It offers implants, instruments and health care products. So …
  • ShaMaran Petroleum Corp (SNM):石油・ガス:M&Aディール及び事業提携情報
    Summary ShaMaran Petroleum Corp (ShaMaran Petroleum), formerly Bayou Bend Petroleum Ltd is an independent oil and gas exploration and development company. The corporation explores, produces, and develops oil and gas assets. It holds interests and operates Atrush petroleum property located in Kurdist …
  • Nampak Limited:企業の戦略・SWOT・財務情報
    Nampak Limited - Strategy, SWOT and Corporate Finance Report Summary Nampak Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Adaptimmune Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Adaptimmune Ltd (Adaptimmune), a subsidiary of Adaptimmune Therapeutics Plc is a clinical stage biotechnology company that develops T-cell therapy products for the treatment of cancer. The company’s pipeline peptides include NY-ESO TCR used to treat cancer cells, MAGE A-10 TCR used for the t …
  • Papa John’s International, Inc.:戦略・SWOT・企業財務分析
    Papa John's International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Papa John's International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Taiwan High Speed Rail Corporation
    Taiwan High Speed Rail Corporation - Strategy, SWOT and Corporate Finance Report Summary Taiwan High Speed Rail Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • LivaNova PLC (LIVN):企業の財務・戦略的SWOT分析
    LivaNova PLC (LIVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Hamburg Commercial Bank:企業の戦略・SWOT・財務分析
    Hamburg Commercial Bank - Strategy, SWOT and Corporate Finance Report Summary Hamburg Commercial Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • WEC Energy Group Inc:発電所・企業SWOT分析
    WEC Energy Group Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • Xcel Energy Inc (XEL)-石油・ガス分野:企業M&A・提携分析
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • Gazprom Marketing & Trading Ltd:企業の戦略的SWOT分析
    Gazprom Marketing & Trading Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • ESSA Pharma Inc (EPI)-製薬・医療分野:企業M&A・提携分析
    Summary Essa Pharma Inc (Essa Pharma) is a clinical-stage pharmaceutical company that carries out the development of small molecule drugs for the treatment castration-resistant prostate cancer (CRPC). The company’s lead product candidate, EPI-506, disrupts androgen receptor (AR) transcriptional acti …
  • The Co-Operators Group Limited:企業の戦略的SWOT分析
    The Co-Operators Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆